» Articles » PMID: 39772026

Computationally Optimized Hemagglutinin Proteins Adjuvanted with Infectimune Generate Broadly Protective Antibody Responses in Mice and Ferrets

Overview
Date 2025 Jan 8
PMID 39772026
Authors
Affiliations
Soon will be listed here.
Abstract

Standard-of-care influenza vaccines contain antigens that are typically derived from components of wild type (WT) influenza viruses. Often, these antigens elicit strain-specific immune responses and are susceptible to mismatch in seasons where antigenic drift is prevalent. Thanks to advances in viral surveillance and sequencing, influenza vaccine antigens can now be optimized using computationally derived methodologies and algorithms to enhance their immunogenicity. Mice and ferrets that had been previously exposed to historical H1N1 and H3N2 influenza viruses were vaccinated intramuscularly with bivalent mixtures of H1 and H3 recombinant hemagglutinin (rHA) proteins, which were generated using a computationally optimized broadly reactive antigen (COBRA) design methodology. The vaccine antigens were mixed with a cationic lipid nanoparticle adjuvant, Infectimune, which promotes both humoral and cellular immune responses. Mice and ferrets vaccinated with Infectimune and COBRA rHAs elicited protective antibody titers against panels of H1N1 and H3N2 influenza viruses isolated over the past 10 years. These animals also had antibodies that neutralized numerous modern H1N1 and H3N2 influenza viruses in vitro. When challenged with the A/Victoria/2570/2019 H1N1 influenza virus, the COBRA rHA vaccinated animals had minimal weight loss, and no detectable virus was present in their respiratory tissues on day 3 post-infection. These results demonstrate that COBRA rHA vaccines formulated with Infectimune elicit protective antibody responses against influenza strains, which were isolated across periods of time when standard-of-care vaccines were frequently reformulated, thus reducing the need to update vaccines on a nearly annual basis.

References
1.
Guzman C . Next Generation Influenza Vaccines: Looking into the Crystal Ball. Vaccines (Basel). 2020; 8(3). PMC: 7563445. DOI: 10.3390/vaccines8030464. View

2.
Dashti F, Raisi A, Pourali G, Razavi Z, Ravaei F, Nahand J . A computational approach to design a multiepitope vaccine against H5N1 virus. Virol J. 2024; 21(1):67. PMC: 10953225. DOI: 10.1186/s12985-024-02337-7. View

3.
Jacobsen H, Rajendran M, Choi A, Sjursen H, Brokstad K, Cox R . Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for Protection in a Serum Transfer Mouse Challenge Model. mBio. 2017; 8(5). PMC: 5605943. DOI: 10.1128/mBio.01463-17. View

4.
Lee H, Shim E, You S . Immunodominance hierarchy of influenza subtype-specific neutralizing antibody response as a hurdle to effectiveness of polyvalent vaccine. Hum Vaccin Immunother. 2018; 14(10):2537-2539. PMC: 6284502. DOI: 10.1080/21645515.2018.1482172. View

5.
Huang Y, Franca M, Allen J, Shi H, Ross T . Next Generation of Computationally Optimized Broadly Reactive HA Vaccines Elicited Cross-Reactive Immune Responses and Provided Protection against H1N1 Virus Infection. Vaccines (Basel). 2021; 9(7). PMC: 8310220. DOI: 10.3390/vaccines9070793. View